Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Repinotan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 12/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 8/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Repinotan SCHEMBL29376954 | 1.00 | HTR1A (1.00) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL678644 | 1.00 | HTR1A (1.00) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL29711567 | 0.99 | HTR1A (0.98) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL6325494 | 0.99 | HTR1A (0.98) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL6333948 | 0.99 | HTR1A (0.98) | HTR1AACHEHTR1DCA12CA9 | |
| Repinotan SCHEMBL1649375 | 0.98 | HTR1A (0.96) | HTR1AACHEHTR1DCA12CA9 | |
| SCHEMBL7837327 | 0.90 | HTR1A (0.81) | HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL7841791 | 0.89 | HTR1A (0.80) | HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL6326346 | 0.89 | HTR1A (0.79) | HTR1AACHE | |
| SCHEMBL8971004 | 0.86 | HTR1A (0.75) | HTR1AACHECA12CA9ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5585392-A | TREATING OR PREVENTING STROKES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | claimed |
| US-5506246-A | Method for treating depression using substituted aminomethyltetralins and their heterocyclic analogues | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-09 | — | — | US | claimed |
| US-5364857-A | Combination having a neuroprotective effect | TROPONWERKE GMBH & CO KG (DE) | 1994-11-15 | — | — | US | claimed |
| EP-0352613-B1 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1994-04-20 | — | — | EP | claimed |
| EP-0545120-A2 | Combination of 5-HT2-receptor antagonists and 5-HT1A-receptor agonists with neuroprotective effect | Troponwerke GmbH & Co. KG (DE) | 1993-06-09 | — | — | EP | claimed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | claimed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | claimed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| EP-2316469-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316468-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2266590-A2 | Active agent delivery sytems and methods for protecting and administering active agents | Shire LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-5506246-A | Method for treating depression using substituted aminomethyltetralins and their heterocyclic analogues | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-09 | — | — | US | disclosed |
| US-5364857-A | Combination having a neuroprotective effect | TROPONWERKE GMBH & CO KG (DE) | 1994-11-15 | — | — | US | disclosed |
| EP-0352613-B1 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1994-04-20 | — | — | EP | disclosed |
| US-5300523-A | Binding serotonin receptors, treating nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-05 | — | — | US | disclosed |
| EP-0545120-A2 | Combination of 5-HT2-receptor antagonists and 5-HT1A-receptor agonists with neuroprotective effect | Troponwerke GmbH & Co. KG (DE) | 1993-06-09 | — | — | EP | disclosed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | HTR1A 2543/4885ACHE 2215/4885HTR1D 3466/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | HTR1A 4290/4885ACHE 2453/4885HTR1D 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.